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Despite the excellent overall prognosis, unpredictable breast cancer recurrences and deaths also occur among T1N0M0 patients. We
have evaluated clinically applicable methods for identifying aggressive outcome in T1N0M0 breast cancer. The material is based on
aggressive T1N0M0 invasive ductal and lobular carcinomas diagnosed in Turku University Hospital and Jyva ¨skyla ¨ Central Hospital,
Finland, during 1987–1997. We studied all the T1N0M0 breast cancers that had led to recurrency or death (n¼21, 95% T1cN0M0)
during the follow-up period (4–14 years). The study is based on statistical analyses of matched case–control data in which the
prognostic factors of each individual patient with aggressive disease were compared with control patients (n¼45) individually
matched by tumour size, age at diagnosis, histological type of tumour and length of follow-up. The cancer cases were examined for
clinically applicable conventional and immunohistochemical pathologic prognostic factors. High Ki-67 immunopositivity was the
strongest prognosticator of breast cancer death or recurrence in T1N0M0 breast cancer. Also, high p53 immunopositivity, low
oestrogen receptor immunopositivity and Her-2/neu oncogene amplification by chromogen in situ hybridisation were reliable
indicators of unfavourable outcome. Our statistical methods also allowed us to determine for the present material a range of clinical
significance for each immunohistochemical prognostic feature with the associated relative risk for breast cancer death and recurrence.
The paper suggests guidelines for predicting aggressive outcome in T1N0M0 breast cancer.
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In recent years, mammographic screening has made it possible to
detect increasingly small invasive breast carcinomas and reduce
the mortality of the disease (Anderson et al, 2000; Heimann et al,
2002; Louwman et al, 2002; Klemi et al, 2003; Tabar et al, 2003).
Small tumour size and axillary lymph node negativity (T1N0M0)
are significant indicators of excellent outcome in invasive breast
cancer justifying local treatment as the only form of therapy (Bergh
and Holmquist 2001; Colpaert et al, 2001; Isaacs et al, 2001;
Morabiot et al, 2003). However, unpredictable breast cancer
recurrences and deaths occur also among the group of patients
with T1N0M0 breast cancers. Identifying aggressive disease and
unfavourable outcome is essential for those T1N0M0 breast cancer
patients who would benefit from adjuvant therapy.
In the present study, we analyse the strength of association
between clinical prognostic variables and aggressive cancer in
order to determine clinically applicable guidelines for identifying
aggressive outcome in T1N0M0 invasive breast cancer. Usually in
this kind of study approach, one must be prepared for huge
numbers of specimens and exhaustive work in order to adjust the
effect of the relevant confounders. We have solved this problem by
strict data collection. The power of this study is in the matched
case–control design of the data and the sophisticated statistical
methods that allow us to evaluate efficiently the main prognostic
factors and at the same time to take into account the prior well-
known central confounding variables. The approach of individu-
ally matched case–control design shows that by elaborating
conventional prognostic factors – Ki-67 proliferation index, p53
proto-oncogene expression, oestrogen hormone receptor and Her-
2/neu proto-oncogene amplification detected by in situ hybridisa-
tion – with quantitative and statistical methods it is possible to
intensify the prognostication of T1N0M0 breast cancer.
MATERIALS AND METHODS
Patient material
The material was analysed comparing two patient groups. The first
group (aggressive cancers, n¼21) involved all the aggressive
T1N0M0 patients dead of breast cancer or detected with
recurrency in two Finnish central hospitals during 1987–1997
(follow-up 4–14 years). These patients were individually matched
with T1N0M0 patients alive of breast cancer with no detectable
recurrency during the follow-up period (control cancers, n¼42).
The control cancers were selected as accurately as possible in order
to match each of the individual aggressive cancer patient by
tumour size, age at diagnosis and histological type of tumour.
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the respective control cancer patients were allowed to differ no
more than 2mm in tumour diameter and no more than 8 years in
age at diagnosis. Moreover, in order to avoid the influence of the
length of follow-up time on the results, the survival time of each
individual control cancer patient was determined equal to or
longer than that of the corresponding individual aggressive cancer
patient. Table 1 shows the characteristics of groups of aggressive
cancer and control cancer cases.
All patients had been treated with radical or modified radical
mastectomy or conservation surgery with axillary evacuation.
None of the patients had received preoperative radiation therapy
or preoperative adjuvant treatment. The histological grading of
carcinomas was performed according to Elston et al (1998). The
number of axillary lymph nodes examined was recorded when
obtainable from patient records. Complete follow-up histories and
peri-operative tissue specimens from the primary tumours were
available for each patient. The follow-up examination was carried
out every 3 months during the first postoperative year, every 6
months during the second and third postoperative years and
thereafter yearly, until 5 years of follow-up was completed. The
mean follow-up period was 7 years (range from 4 years and 9
months to 14 years and 9 months).
Clinical follow-up investigation was completed by chest and
bone radiographs, soft tissue ultrasound examinations and
laboratory tests reflecting bone and liver metabolism. Recurrent
disease was verified by cytological and histological samples or
radiographs in case of bone metastasis. The causes of death were
based on autopsy reports, death certificates and patient files from
the Finnish Cancer Registry.
Immunohistochemistry
The primary diagnosis of invasive ductal or lobular breast
carcinoma was verified in van Gieson-stained slides and the
corresponding areas of 5mm thick sections were stained for
oestrogen (ER) and progesterone (PR) receptors, Ki-67 prolifera-
tion index and p53 oncogene. Immunohistochemical stainings
(IHC) were performed with the TechMate 500 immunostainer and
a peroxidase/diaminobenzidine (DAB) multilink detection kit
(DAKO, Denmark), which is based on an indirect streptavidin–
biotin method. Antigen retrieval was carried out using a
microwave oven. Monoclonal antibodies against human ER a,
Ki-67 antigen and p53 oncogene were supplied by Dako (DAKO,
Denmark) and applied with dilutions 1:40, 1:100 and 1:300,
respectively. Monoclonal antibody against human PR (dilution
1:20) was provided by Novocastra (Novocastra Laboratories Ltd,
UK). Slides were counterstained with Mayer’s haematoxylin.
Chromogenic in situ hybridisation
Her-2/neu proto-oncogene was detected by chromogenic in situ
hybridisation (CISH). CISH was performed on 3mm formalin-fixed
paraffin-embedded tissue sections verified with cancer tissue as
described above. Pretreatment of the sections was performed in
citric acid and microwave oven. After the pretreatment, the
specimens were digested with acidic pepsin solution. Digoxigenin-
labelled c-erbB-2 probe (SPOT-Light HER2 DNA Probe, Zymed
Inc., USA) was hybridised on the sections overnight and the probes
were detected with horseradish peroxidase/diaminobenzidine
system by the SPOT-Light CISH Polymer Detection Kit (Zymed
Inc., USA). Finally, the sections were counterstained with Mayer’s
haematoxylin.
Interpretation of IHC and CISH
Interpretations of IHC were standardised in evaluation sessions
between two pathologists (PK and PK). Special consideration was
placed on the selection of fields for evaluating IHC in order to
ensure validity and reproducibility of results. First, in each case, we
chose the representative slide, placing special emphasis on the
preservation of histological details. Next, we identified the area of
the actively proliferating cells at the border of the most cellular
part of the tumour, rejecting areas showing necrosis and
inflammation. Interpretation was performed by assessing with
 40 objective three separate evaluation areas with a total of 300
malignant cells. The fractions of positive cells (in percentages) as
compared to positive control samples from the same staining
series were registered. The CISH slides were analysed under an
ordinary transmitted light microscope with  40 and  60
objectives (MN). In analysing CISH, the hybridisation results were
registered in two classes (0 and þ). The Her-2/neu proto-
oncogene was considered to be amplified (þ) if the copy number
of the gene was six or more per cell (Tanner et al, 2001).
Statistical analysis
The statistical analysis surveyed the routine clinico-pathological
prognostic factors of the patient material. The data were collected
according to the individually matched case–control design. This
design ascertained that there was a controlled number of
aggressive and control cancers that were matched with primary
confounding factors. It followed from the matching that in the
comparisons of cases and controls the confounders (used in the
matching) were taken into account and there was no need to
include the confounders into the statistical models. This led to
more efficient estimation of associations of the prognostic
variables of main interest. Moreover, it was not necessary to make
assumptions about the association structure of confounders.
Without matching it would have been possible to adjust the
confounders equally efficiently only if the data had been
enormously large. Even though the descriptive statistics in the
results are shown separately for groups of aggressive and control
cancers, the statistical analysis was based on stratification
according to matched sets of patients. The prognostic associations
of the variables with outcome of cancer were statistically analysed
by conditional logistic regression analysis that takes into account
the stratification due to the individual matching of the case and
controls. In addition to P-values, the results were quantified using
odds ratios (ORs) with 95% confidence intervals (CIs). Because the
Table 1 Clinicopathological characteristics of the patient material
(n¼66)
Variable Aggressive cancers Matched control cancers
Tumor size (mm) 14.2 14.8
Mean 4–20 7–20
Range
Age (year) 56.9 53.6
Mean 40–73 39–71
Range
Follow-up (years) 5 8
Mean 4.7–11.7 4.7–14.7
Range
Histological type 96.3 84.4
Ductal (%) 3.7 15.6
Lobular (%)
Histological grade 12.2 32.6
I (%) 61.5 53.5
II (%) 19.3 13.9
III (%)
Prognosis of T1N0M0 breast cancer
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applying exact methods instead of the commonly used approx-
imate asymptotic calculations (Breslow and Day, 1980; Hosmer
and Lemeshow, 2000). Statistical computations were performed
using SAS System for Windows, release 8.2/2001 and LogXact-4 for
Windows, 2000 (Cytel Software Corporation)
RESULTS
Summaries of IHC, CISH and histological grade are presented in
Table 2. In univariate analysis (Table 3), the strongest single
feature predicting breast cancer death or recurrence was Ki-67
(P¼0.002). Statistically significant prognostic features were also
p53 (P¼0.004) and ER (P¼0.020). Her-2/neu was associated with
a close-to-significant prognostic value (P¼0.069). Instead, PR,
ductal or lobular histological type, histological grade or number of
investigated axillary lymph nodes were not statistically significant
prognostic features in our material.
In statistical analysis, correlations could be expected between
the strongest prognosticator, Ki-67, and other prognostic factors.
In order to find out if ER, p53 or Her-2/neu had independent
prognostic associations with aggressiveness of the disease, we
analysed them by taking into account Ki-67. In a Ki-67-adjusted
analysis, the directions of associations remained the same.
However, ER, p53 or Her-2/neu were not found to give a
significant addition to the prediction after taking into account
Ki-67 (Table 3).
In order to improve the routine clinical applicability of the
prognostic features in T1N0M0 breast cancer, we set out to
determine guidelines for interpreting IHC of Ki-67, p53 and ER.
The guidelines were based on the present material testing the
prognostic significance of six cutpoints of IHC (5, 10, 15, 20, 25
and 30%). In our material, the most significant cutpoint (Figure 1)
for Ki-67 was 10%. Patients with Ki-67 positivity in more than 10%
of cancer cells were associated with an 11-fold odds of breast
cancer death or recurrency compared to the patients with Ki-67
positivity in less than 10% of cancer cells (Table 4). Correspond-
ingly, patients with higher than 30% positivity in p53 were
associated with a 10-fold odds for unfavourable outcome of
disease. As to ER, the most significant cutpoint was at 20% of ER-
positive cancer cells. However, in our material, patients with less
than 20% of ER positivity were not significantly (P¼0.092)
associated with unfavourable outcome as compared with patients
with more ER positivity (OR¼3.63, 95% CI¼0.79–22.45).
Table 3 Results of unadjusted and adjusted exact conditional logistic regression analysis of all prognostic features presented by ORs with 95% CIs in the
material of 66 T1N0M0 breast cancers
Unadjusted analysis Adjusted for Ki-67
Variable P OR 95% CI P OR 95% CI
Ki-67 0.001 2.6 1.30–7.15
p53 0.003 1.4 1.09–1.97 0.137 1.22 0.93–1.73
ER 0.020 0.8 0.71–0.98 0.219 0.9 0.75–1.07
CISH 0.069 3.9 0.78–24.70 0.683 1.4 0.20–9.17
PR 0.452 0.9 0.81–1.10
N 0.432 1.1 0.82–1.61
Histology 0.398 0.3 0.01–2.83
Grade 0.177 2.0 0.74–6.74
Ki-67, p53, ER, PR¼immunohistochemically detected positivity of Ki-67, p53, estrogen and progesterone hormone receptors, CISH¼amplification of Her-2/neu, N¼number of
examined axillary lymph nodes, histology¼histological type (ductal or lobular), grade¼WHO grade I–III.
Table 2 Means (s.d.) of immunohistochemical stainings (percentage of
positive cancer cells) and CISH (per cent of cases classified as positive) in
the aggressive and control cancers
Variable Aggressive cancers Control cancers
Ki-67 26.7 (15.4) 16.5 (11.3)
p53 35.6 (38.3) 17.0 (26.8)
ER 49.0 (41.4) 70.6 (35.5)
PR 49.6 (38.8) 60.2 (35.4)
MAI 10.0 (9.2) 7.9 (9.5)
CISH (%) 6.1 4.0
Ki-67, p53, ER, PR¼immunohistochemically detected positivity of Ki-67, p53,
estrogen and progesterone hormone receptors, CISH¼amplification of Her-2/neu.
P = 0.05
0
51 0
Cutpoint
Ki-67
ER
p53
15 20 25 30
Figure 1 Prognostic value of immunopositivity of six cutpoints (5, 10, 15,
20, 25 and 30%) for Ki-67, ER and p53 in T1N0M0 breast cancer. The
range of statistical significance (conditional logistic regression analysis) for
each of the three features is shown under the line representing P-values
equal or lower than 0.05. The most significant cutpoints are the lowest
points of the curve at 10% for Ki-67, at 20% for ER and at 30% for p53.
Table 4 The most significant cutpoints for Ki-67, ER and p53
immunohistochemistry in our material of T1N0M0 breast cancer, and the
relative risks (RRs) of breast cancer death or recurrence with P-values
associated with each cutpoint
Variable Cutpoint (%) P RR
Ki-67 10 0.007 11
ER 20 0.009 4
p53 30 0.013 10
Prognosis of T1N0M0 breast cancer
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In recent years, mammographic screening has made it possible to
detect increasingly small invasive breast carcinomas and reduce
the mortality of the disease (Anderson et al, 2000; Heimann et al,
2002; Louwman et al, 2002; Klemi et al, 2003; Tabar et al, 2003).
Identifying aggressive disease in T1N0M0 breast cancer would give
valuable information for planning adjuvant treatments.
The limited number of aggressive T1N0M0 breast cancer cases –
as fortunate as it is for breast cancer patients – hampers clinical
examination of the disease. In the two Finnish central hospitals
involved in this study, a total of 21 T1N0M0 cases were reported
with recurrent disease or breast cancer death during 1987–1997. In
the present study, this problem was dealt with statistical
techniques that are developed just in these kinds of situations.
Firstly, with the individual matching, it was possible to control
primary confounders and to ascertain that data from cases and
controls corresponded to each level of the confounders. Secondly,
with the conditional logistic regression analysis, it was possible to
take into account the matching and perform the multivariate
analysis. Thirdly, the matching (or stratification) made it possible
to perform exact statistical calculations in the logistic analysis.
In addition to conventional morphological examination, ER, PR,
Ki-67, p53 and Her-2/neu are highly established prognostic
markers of invasive breast cancer. Also our analysis revealed that
high Ki-67 and p53 immunopositivity, low ER immunopositivity
and Her-2/neu oncogene amplification are the most reliable
indicators of unfavourable outcome in T1N0M0 breast cancer. In
multivariate analysis, high Ki-67 immunopositivity was the
strongest individual prognosticator of breast cancer death or
recurrence.
We further aimed at trying to intensify the value and
applicability of Ki-67, p53 and ER immunohistochemistry by
producing practical guidelines for their interpretation in the
clinical setting. Based on the present material, we determined a
range of clinical significance for each of the immunohistochemical
prognostic features (Figure 1). In our material ,the range of
optimal cutpoints for Ki-67 immunopositivity was 10% or above.
Correspondingly, the cutpoint range for p53 was 30% or above and
for ER 20%.
In literature, the criteria for determining Ki-67, p 53 and ER
immunopositivity in breast cancer vary between 5 and 80% of
cancer cells (Seymour et al, 1990; Jackson et al, 1990; Barnes and
Millis, 1995; Goulding et al, 1995; Wishart et al, 2002). Also, a
number of interpretation guidelines have been reported including
categorical methods (Barnes and Millis, 1995), semiquantitative
scoring systems (McCarty et al, 1985) and multivariate methods
combining several interpretation features (Elston et al, 1998).
Despite the convincing evidence on the prognostic value of IHC of
Ki-67, p53 and ER in breast cancer, no universally accepted
guidelines have been available for their interpretation this far.
According to literature, reported poor specificity of ER immuno-
histochemistry in breast cancer can result in lower response rates
to hormone therapy (McClelland et al, 1986; Robertson et al, 1992;
Goulding et al, 1995). These facts emphasise the need for
established clinically tested and uniformly practised interpretation
guidelines for IHC in breast cancer. By using in situ hybridisation,
we were able to avoid many of the difficulties encountered in the
immunohistochemical analysis of Her2/neu (Tanner et al, 2001;
Anttinen et al, 2003).
The small number of cases available for examination inevitably
has its drawbacks on the conclusions of this paper. However, the
patient material in the present study can be considered unique
because of the accurate and careful selection of the control
material as close as possible to perfect match between individual
patient cases. The present results are consolidated by the
appropriate study design of individually matched case–control
approach. The uniformity and cohesiveness of the patient
material emphasise the value of the obtained prognostic
correlations.
Our paper emphasises the need for uniform prognostic methods
in T1N0M0 breast cancer. In clinical pathology, no universally
accepted cut points are available for the interpretation of
immunohistochemical prognostic factors in breast cancer. Ki-67,
p53 and ER immunohistochemistry, and Her-2/neu amplification
analysis by CISH involves simple, standardised and established
methods that can provide valuable prognostic information on
T1N0M0 breast cancer. In the present paper, we summarise
guidelines for identifying unfavourable outcome in T1N0M0 breast
cancer. It is realistic to state that the cutpoints based on such
limited data must be interpreted with care. However, in practice, a
variety of cutpoints are clinically applied although none of them
are based on careful analysis of any data – especially not of data for
T1N0M0 tumours. The numerical cutpoints shown in the present
study can give preliminary guidelines for clinical practice although
our findings naturally need further verification. However, our
results show that such guidelines can benefit individual breast
cancer patients with more efficient and accurate treatment
decisions.
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